Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

New Data Further Demonstrate PARP Inhibitor Impact in Ovarian Cancer

November 29th 2018

David O’Malley, MD, discusses the findings from the SOLO-1 and QUADRA studies, as well as the future of PARP inhibition in ovarian cancer.

Upfront Options Continue to Expand in Advanced Ovarian Cancer

November 29th 2018

Trung Nguyen, DO, MBA, discusses the evolving options for the treatment of patients with newly diagnosed advanced ovarian cancer.

Surgery Remains Standard of Care in Advanced Ovarian Cancer

November 28th 2018

Amer Karam, MD, discussed surgical options for patients with advanced-stage ovarian cancer and the emergence of neoadjuvant chemotherapy.

Novel Agents and the Future Treatment of Ovarian Cancer

November 28th 2018

The Role of I-O in Platinum-Resistant Recurrent OC

November 28th 2018

ADC in Platinum-Resistant Ovarian Cancer

November 28th 2018

PARP Inhibitors: Which One Should We Use?

November 28th 2018

Maintenance Therapy for Recurrent Advanced Ovarian Cancer

November 28th 2018

Factors in Choice of Treatment for Recurrent Ovarian Cancer

November 28th 2018

Role of HIPEC in Newly Diagnosed Advanced Peritoneal Cancer

November 28th 2018

PARP Combinations: The Future

November 28th 2018

The Evolution of Single-Agent PARP Inhibitors

November 28th 2018

Highly Anticipated Data from the SOLO-1 Trial

November 28th 2018

Upfront Systemic Therapy in Addition to Chemo?

November 28th 2018

Recommendations for Molecular Testing in Advanced OC

November 28th 2018

Neoadjuvant Chemo VS Cytoreductive Surgery in OC

November 28th 2018

Amid Mixed Data, Immunotherapy Remains a Focal Point in Ovarian Cancer

November 27th 2018

Oliver Dorigo, MD, PhD, discusses the promise of immunotherapy in ovarian cancer.

Expert Identifies Biggest Shifts in Ovarian Cancer Paradigm

November 27th 2018

Jonathan S. Berek, MD, MMS, outlines the changing paradigm of ovarian cancer.

PARP Inhibitors Continue to Lead Progress in Ovarian Cancer

November 26th 2018

Elisabeth Diver, MD, discusses ongoing advances with PARP inhibitors in ovarian cancer.

Dr. Westin on Emerging PARP Inhibitors in Ovarian Cancer

November 20th 2018

Shannon N. Westin, MD, MPH, clinical investigator, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses PARP inhibitors being tested in clinical trials.